ASH: Takeda details Ninlaro's miss in scrapped AL amyloidosis trial

Back in June, Takeda scrapped a Ninlaro trial in the rare disease light-chain (AL) amyloidosis. Saturday, it shared the data behind that decision—results exec say they’re excited to get into the public domain.